Remedium Lifecare Ltd. (BSE: 539561), a company engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, sets the record date for the bonus issue of shares as 06 July 2024 (if approved by shareholders in AGM). Recently, the board approved and recommended a Bonus Issue of 3 Equity Shares for every 1 Equity Share held as on the Record date decided for this purpose, subject to approval from members and appropriate authorities.
For the year ended 31 March 2024, the company recorded revenues of Rs. 4042 Crores, a
growth of 692% YoY. The EBITDA jumped 312% YoY, from Rs. 8 Crores to Rs. 33 Crores (FY24). The PBT grew 614%, from Rs. 7 Crores (FY23) to Rs. 50 Crores (FY24). PAT jumped 560% YoY, from Rs. 5 Cr (FY23), to Rs. 33 Crores (FY24). The EPS was reported at Rs. 90.92 per share.
Remedium Lifecare Ltd., a company engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, has bolstered its performance and
presence within the pharmaceutical and healthcare domains by trading amino isophthalic acid, tellurium oxide, grignard reagent, iodine, selenium metal powder, trimethyl sulfoxonium iodide (TMSI). As a leading contract trader and brand owner of advanced intermediates and APIs, Remedium has shifted its paradigm into the trading of intermediates and APIs.
Reflecting the ethos of its Chairman, who believes in “working hard in silence and letting
success make the noise,” Remedium is dedicated to upholding uncompromising quality standards. Remedium has consistently raised the industry’s benchmarks through its commitment to developing intermediates (KSMs & CRMs) and APIs that deliver unique value to patients and societies worldwide. Adapting swiftly to evolving demands, the company has
emerged as one of the fastest-growing organizations in the global pharmaceutical industry.